Open Veils · Answer
Lithiun orotate
The suppressed record on lithium orotate predates the current supplement boom by decades, with clinical use documented in Eastern European and Soviet medicine long before Western regulatory bodies took notice. The orotate carrier is the central controversy: researchers like Hans Nieper proposed in the 1970s that orotate ligands act as mineral transporters, shepherding lithium across the blood-brain barrier at doses orders of magnitude below pharmaceutical carbonate. A 2026 PubMed commentary challenges whether stable lithium orotate survives stomach acid at all — but this dissociation argument equally applies to dozens of accepted mineral chelates, and the debate itself confirms the mechanism is worth resolving. The neuroprotective-at-microdose angle, now circulating in Alzheimer's research circles per Medscape (Jan 2026), is the thread alternative practitioners have pulled for fifty years.
Evidence
- Gary Null and orthomolecular researchers such as Jonathan Wright picked up Nieper's framework in the 1990s, documenting anecdotal series of patients using lithium orotate for mood regulation, aggression and cognitive protection without the thyroid and renal side-effect profiles associated with carbonate.
- The environmental epidemiology angle is the most striking corroboration.
- A 2026 PubMed letter challenges the orotate-specific mechanism directly, arguing acid-base chemistry predicts dissociation in the stomach, leaving lithium carbonate and lithium orotate pharmacokinetically equivalent.
- Medscape's January 2026 coverage of lithium orotate and Alzheimer's prevention describes the compound as an 'amyloid-evading salt' and calls the findings 'exciting,' while noting trials are incomplete.
- His clinical observations on mood stabilisation, alcoholism reduction and neurodegeneration predate the supplement industry's interest by two decades.
